Lv1
70 积分 2022-07-13 加入
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
5个月前
已完结
Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells
8个月前
已完结
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
10个月前
已完结
GTP signaling links metabolism, DNA repair, and responses to genotoxic stress
11个月前
已完结
Drugging RAS: Moving Beyond KRASG12C
1年前
已完结
The polarity protein PARD3 and cancer
1年前
已完结
Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in Non-Small Cell Lung Cancer with a special focus on KRAS G12C
1年前
已完结
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
1年前
已完结
Remodeling oncogenic transcriptomes by small molecules targeting NONO
1年前
已完结
皖公网安备34019202002308
